To evaluate the durability of PRDM1/NR4A3 double KO CAR T-cell therapeutic efficacy, we conducted a study in which CAR T-cell-treated NSG mice were rechallenged with NALM-6 cells 40 days after the initial leukemia cell transfer. The gene discussed is NR4A3; the disease is leukemia.